Amy
- Quote
-
I feel so fortunate to be able to help support patients and do what I do.
- First Name
- Amy
- Credential
- Nurse Case Manager
Information provided by the NCM is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified and licensed physician or other healthcare provider regarding your medical condition, treatment, and healthcare needs.
What inspires the My VYVGART Path NCMs
Vivi
- Quote
-
Being there for patients is the best gift I can ever ask for.
- First Name
- Vivi
- Credential
- Nurse Case Manager
Karen
- Quote
-
It is a great privilege to support patients during their treatment journey.
- First Name
- Karen
- Credential
- Nurse Case Manager
Fred
- Quote
-
The most rewarding part of my role is being in a patient’s corner when they need it.
- First Name
- Fred
- Credential
- Nurse Case Manager
Karen
- Quote
-
I am passionate about educating patients and empowering them to manage their disease.
- First Name
- Karen
- Credential
- Nurse Case Manager
Renay
- Quote
-
The challenge of patient support is real, and the reward is great.
- First Name
- Renay
- Credential
- Nurse Case Manager
Deborah
- Quote
-
Empowered patients are more engaged and confident in decision-making regarding their health.
- First Name
- Deborah
- Credential
- Nurse Case Manager
Jess
- Quote
-
Helping patients is a very rewarding profession, and I was meant to be in it.
- First Name
- Jess
- Credential
- Nurse Case Manager
Cari
- Quote
-
I enjoy feeling purposeful in my work with rare disease patients and helping them on their journey.
- First Name
- Cari
- Credential
- Nurse Case Manager
Jennifer
- Quote
-
It is a privilege to feel as though you’ve made a difference in a patient’s journey.
- First Name
- Jennifer
- Credential
- Nurse Case Manager
Nikki
- Quote
-
I work to enhance the patient journey effectively and efficiently.
- First Name
- Nikki
- Credential
- Nurse Case Manager
How to enroll in My VYVGART Path
There are 2 options to enroll once your doctor has prescribed you VYVGART Hytrulo:
Once enrolled in My VYVGART Path, you will receive a call from an NCM to welcome you into the program. A welcome kit will be mailed to you that includes a wide range of helpful resources.
Resources to help support your treatment journey
My VYVGART Path brochure
See how the My VYVGART Path Patient Support Program can empower you on your treatment journey.
Cost and coverage
Find resources and information that may help you navigate coverage for treatment.
Join the program
Learn how you can get enrolled in the patient support program, My VYVGART Path.
Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:
- have an infection or fever.
- have recently received or are scheduled to receive any vaccinations.
- have any history of allergic reactions.
- have kidney (renal) problems.
- are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
- Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
- are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
VYVGART HYTRULO can cause side effects which can be serious, including:
- Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
- fever
- chills
- frequent and painful urination
- cough
- pain and blockage of nasal passages
- wheezing
- shortness of breath
- sore throat
- excess phlegm
- nasal discharge
- Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
- rash
- swelling of the face, lips, throat, or tongue
- shortness of breath
- hives
- trouble breathing
- low blood pressure
- fainting
- Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
- high blood pressure
- chills
- shivering
- chest, stomach, or back pain
The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?
VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
It is not known if VYVGART HYTRULO is safe and effective in children.
Please see full Prescribing and Patient Information for VYVGART HYTRULO.
Dosage forms and strengths:
VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.
IMPORTANT SAFETY INFORMATION
Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:
- have an infection or fever.
- have recently received or are scheduled to receive any vaccinations.
- have any history of allergic reactions.
- have kidney (renal) problems.
- are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
- Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
- are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
VYVGART HYTRULO can cause side effects which can be serious, including:
- Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
- fever
- chills
- frequent and painful urination
- cough
- pain and blockage of nasal passages
- wheezing
- shortness of breath
- sore throat
- excess phlegm
- nasal discharge
- Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
- rash
- swelling of the face, lips, throat, or tongue
- shortness of breath
- hives
- trouble breathing
- low blood pressure
- fainting
- Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
- high blood pressure
- chills
- shivering
- chest, stomach, or back pain
The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?
VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
It is not known if VYVGART HYTRULO is safe and effective in children.
Please see full Prescribing and Patient Information for VYVGART HYTRULO.
Dosage forms and strengths:
VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.
Facebook
Twitter
PinterestThis site is intended for patients and caregivers.
Disclaimer | Privacy Policy | Contact Us |
VYVGART and VYVGART Hytrulo are registered trademarks of argenx.
LIVE VYVIDLY and THAT’S LIVING VYVIDLY are trademarks of argenx.
For U.S. audiences only.
©2025 argenx
US-VYV_HYT-24-00525 V2 05/2025
